Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amorfix Life Science
(TSX:
PMN
)
6.000
UNCHANGED
Last Price
Updated: 3:55 PM EDT, Jul 21, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
6.000
Bid (Size)
5.850 (5)
Ask (Size)
8.750 (5)
Prev. Close
6.000
Today's Range
6.000 - 6.000
52wk Range
3.340 - 11.10
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
April 09, 2024
Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS)
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
April 04, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Performance
YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-33.33%
-33.33%
More News
Read More
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
April 01, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
March 11, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
February 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
January 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
January 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
January 03, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
September 08, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
August 21, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
July 17, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Announces Completion of Continuance
July 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
July 10, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
June 30, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
June 29, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 15, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
May 08, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
April 25, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
April 24, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
April 10, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.